Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status

02.04.2024 - Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant ... Seite 1

Related Keywords

,Petros Pharmaceuticals Inc ,Drug Administration ,Nasdaq ,Petros Pharmaceuticals ,Drug Facts Label ,Petro President ,Chief Commercial Officer ,Additional Condition ,Nonprescription Use ,